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Foreword 
On the 21st and 22nd of March, a two-day workshop was organised by the Knowledge for 
Health and Consumer Safety Unit of the Joint Research Centre, on the Role and 
Implementation of Next-Generation Sequencing Technologies in the European Action Plan 
against Antimicrobial Resistance. 
The workshop brought together 15 international experts representing the top expertise in 
the use of NGS to detect the genetic determinants of AMR in diverse fields: clinical, 
human health, animal health, food and environmental monitoring.  Representatives from 
the JRC, EMBL-EBI and standardisation authorities were also present in the discussions. 
The participating experts were: 
Johan Bengtsson-Palme - University of Gothenburg, Sweden 
Thomas Berendonk - Technische Universität Dresden, Germany 
Burton Blais - Canadian Food Inspection Agency, Canada 
Kok Gan Chan - University of Malaya, Malaysia 
Teresa M. Coque - Hospital Universitario Ramón y Cajal (IRYCIS), Spain 
Derrick Crook - University of Oxford, UK 
Matthew Ellington - Public Health England, UK 
Christoph Endrullat - German Institute for Standardization (DIN), Germany 
Dirk Höper - Friedrich-Loeffler-Institut- Federal Research Institute for Animal Health, 
Germany 
Ole Lund - Technical University of Denmark, Denmark 
Jean Yves Madec - Agence nationale de sécurité sanitaire de l’alimentation, de 
l’environnement et du travail, France 
Alan McNally - University of Birmingham  
Thierry Naas - Hôpital de Bicêtre- Service de Bactériologie, France 
Justin O'Grady - University of East Anglia, UK 
Jessica Vamathevan- European Bioinformatics Institute (EMBL-EBI), UK 
Chair: 
Guy Van den Eede - Head of Unit Knowledge for Health and Consumer Safety, JRC. 
Other participants from the Joint Research Centre: 
Alexander Binder - Health in Society Unit, JRC 
Alessia Bogni - Consumer Products Safety Unit, JRC 
Dafni Kagkli - Fraud Detection & Prevention Unit, JRC 
Teresa Lettieri - Water and Marine Resources Unit, JRC 
Valentina Paracchini - Fraud Detection & Prevention Unit, JRC 
Cristian Savini - Food & Feed Compliance Unit, JRC 
Heinz Schimmel - Reference Materials Unit, JRC 
Organising committee: 
Alexandre Angers - Knowledge for Health and Consumer Safety Unit, JRC 
Mauro Petrillo - Knowledge for Health and Consumer Safety Unit, JRC 
Maddalena Querci - Knowledge for Health and Consumer Safety Unit, JRC 
Alex Patak - Knowledge for Health and Consumer Safety Unit, JRC 
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1 Introduction 
 
1.1 Monitoring the rise and spread of Antimicrobial Resistance 
 
Since their discovery, antimicrobials have played an essential role in the treatment of 
infections and have significantly improved the population's health. However, the rise of 
antimicrobial resistance (AMR, i.e. the ability of a microorganism to resist the action of 
an antimicrobial agent) now endangers the status quo of our healthcare system. 
Evidence of antibiotic resistance is growing. For example, an alarming development was 
reported last year for one of the last-resort antibiotics, namely colistin, where a form of 
resistance was discovered that could be readily transferred to other bacteria (Liu et al., 
2016). Researchers first discovered this resistance in China, quickly followed by findings 
– including by the JRC (Petrillo et al., 2016) - of similar resistance patterns in other 
countries, including in Europe. The spread of multiple-drug resistant bacteria already 
causes an estimated 25.000 deaths annually in Europe alone, a toll that is expected to 
increase1. 
For many years, the European Union, as well as other countries and international 
organisations, have been addressing the issue of the rise and spread of AMR. Their work 
includes the establishment of collaborative programs that raise public awareness and aim 
to align international actions in order to maximise their efficacy.  These actions include 
the promotion of research and innovation to identify new antimicrobial compounds, the 
prevention of disease to minimise antimicrobial needs, and public awareness about their 
correct use.   
These efforts depend, among other things, on the establishment of an efficient 
monitoring and surveillance scheme, implemented in a coordinated and international 
framework. This scheme is crucial for understanding the development and diffusion of 
resistance in order to provide relevant risk assessment data and evaluate the 
effectiveness of targeted interventions (see Box 1). 
Box 1.  AMR surveillance  
The importance of an efficient framework for AMR surveillance and the efforts needed for 
its improvement have been stressed in the recent years.   
For example, the WHO's 2014 Antimicrobial Resistance Global Report on Surveillance 
highlighted the existence of gaps in the methodology for integrated surveillance of 
resistance in human and foodborne pathogens and the need for the development of tools 
and standards for harmonized surveillance of AMR (World Health Organization, 2014).  
In October 2015, a Declaration of the G7 Health Ministers stated that "We consider that a 
lack of comparable data on the quantity and kind of use of antibiotics and the prevalence 
of AMR in the population results in an incomplete understanding of the antibiotic 
resistance situation. The availability of comparable international and national data is a 
pre-condition for targeted action within countries"  
(http://www.g8.utoronto.ca/healthG8/2015-berlin.html) 
 
Within the EU, data on surveillance of AMR in human health are compiled and released by 
the European Antimicrobial Resistance Surveillance Network (EARS-Net)2 as part of ECDC 
surveillance. A “One Health” perspective is also encouraged, evaluating the impact of 
                                           
1 http://ec.europa.eu/dgs/health_food-safety/docs/amr_factsheet.pdf 
2 http://ecdc.europa.eu/en/healthtopics/antimicrobial-resistance-and-
consumption/antimicrobial_resistance/EARS-Net/Pages/EARS-Net.aspx 
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antimicrobial resistance in humans, food-producing animals and food; in this optic, every 
year, EFSA and ECDC publish the European Union summary report on antimicrobial 
resistance in zoonotic and indicator bacteria from humans, animals and food (see, for 
example, European Food Safety Authority and European Centre for Disease Prevention 
and Control, 2017). 
In these efforts, the definition of AMR refers to clinical or epidemiological cut-off (ECOFF) 
breakpoints defined by the European Committee on Antimicrobial Susceptibility Testing 
(EUCAST)3. Their significant implementation across European laboratories is an essential 
component of the consistency required for clinical reporting of antimicrobial susceptibility 
results (Brown et al., 2015).  These methods are "phenotypic", meaning that they rely on 
observing the extent to which live bacteria are affected by the antimicrobials.  
1.2 A potential role for Next-Generation Sequencing 
At the end of 2014, a report from the "The Review on Antimicrobial Resistance" stated 
that "advances in genetics, genomics and computer science will likely change the way 
that infections and new types of resistance are diagnosed, detected and reported 
worldwide, so that we can fight back faster when bacteria evolve to resist drugs".4  
Indeed, the potential to predict antibiotics resistance of bacteria by determining the 
sequences of their genomes and the plasmids they host has long been discussed (see 
Box 2). With the advent of Next-Generation Sequencing (NGS) technologies, our modern 
capability to generate a wealth of nucleic acid sequence information - when coupled to 
the appropriate bioinformatics information systems - allows both a profiling of 
microorganisms (as single clones or as a community) and the detection of potential 
antimicrobial activities in a single experiment. 
Box 2. Detection of AMR using DNA sequencing 
An important aspect for the monitoring of antimicrobial resistance using sequencing-
based methods (compared to phenotypic approaches) is the importance to understand 
and take into account the molecular mechanisms of these resistances. Several 
mechanisms have been described in the literature, and include: 
1. The production of an enzyme that digests/metabolizes the antimicrobial. 
2. The production of efflux pumps that remove the drug(s) from within the cell. 
3. The modification, through mutations, of the intracellular target of the antimicrobial so 
that their interaction is lost. 
4. The activation/up-regulation of alternate pathways that allow survival through the 
bypass of the pathway disrupted by the antimicrobial. 
5. The down-regulation of the expression of the pores through which the drug enters the 
bacteria. 
Mechanisms 1-3 generally involve modifications in the pathogen’s DNA sequence and/or 
content through horizontal gene transfers or specific mutations in the endogenous 
genome sequence. As such, these modifications can most probably be efficiently detected 
by sequencing-based methods. Mechanisms 4 and 5, on the other hand, represent 
environmental adaptation through signal transduction pathways and their detection 
through non-phenotypic approaches will likely present a case-by-case challenge.  
In the recent years, a wealth of scientific articles have been published, describing 
development and trials of NGS-based methods in the determination of AMR in various 
contexts, both for the clinic (see, for example, Bradley et al., 2015; Sherry et al., 2013; 
Votintseva et al., 2017), food (see, for example, Hasman et al., 2015), and the 
                                           
3 http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Resistance_mechanisms/ 
EUCAST_detection_of_resistance_mechanisms_v1.0_20131211.pdf 
4 "Antimicrobial Resistance: Tackling a crisis for the health and wealth of nations", December 2014 
5 
 
environment (see, for example, (Bengtsson-Palme et al., 2014, 2016; Noyes et al., 
2016). 
In June 2016, in its conclusions on the next steps under a “One Health” approach to 
combat antimicrobial resistance, the Council of the European Union called upon the 
Commission and the Member States to "align surveillance on AMR in humans, food, 
animals and environment at EU level"5. 
This mention of environmental surveillance on AMR is a challenge with the currently 
available methods. Phenotypic interpretation of AMR for environmental bacteria is 
difficult, largely because there are no guidelines for resistance due to their lack of clinical 
relevance and difficulty (if not impossibility) in culturing them. Still, AMR in non-
pathogenic environmental bacteria could be a crucial factor in the development of 
resistance pathogens due to the potential of horizontal gene transfer of resistance genes 
from non-pathogenic to pathogenic hosts. 
In summary, in the framework of Antimicrobial Resistance detection and monitoring, NGS 
technologies have the potential to: 
 Provide an harmonised link between the surveillance in the environment and in 
the other important aspects of the “One Health” approach (clinic, food and food-
producing animals) 
 Provide added value to the monitoring currently established in each of these fields 
individually. 
For this reason, a Workshop was organised in order to discuss the potential impacts NGS 
technologies could have, specifically, on the current international action plans against 
AMR, as well as to understand the next steps for their development and implementation 
in this context. 
 
  
                                           
5 http://www.consilium.europa.eu/en/press/press-releases/2016/06/17-epsco-conclusions-antimicrobial-
resistance/ 
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2 Summary of the Workshop discussions 
 
Structured in three distinct sessions, the workshop addressed: 
1. The added value of NGS technologies in the AMR action plan 
2. Technical considerations in the determination of AMR using NGS technologies 
3. Challenges in the implementation of eventual NGS-based methods for AMR 
determination 
Because of a large overlap in the discussions of sessions 2 and 3, they are reported as 
one in this document. 
2.1 The added value of NGS technologies in the AMR action plan 
Next-Generation Sequencing, also known as high-throughput sequencing, is the catch-all 
term used to describe a number of different modern technologies that allow nucleic acids 
sequences to be generated much more quickly and cheaply than previously. Coupled with 
Bioinformatics, NGS has revolutionised the study of genomics and microbiology. Applied 
to the prediction of antimicrobial resistance of an unknown isolate or within an 
environmental sample, it could provide many significant advantages to the currently used 
methods, including: 
It can contribute to clinical decision making.  
In a clinical setting, sequencing-based approaches the potential to provide different 
levels of information that can guide treatment with the appropriate antimicrobials.  These 
include a) whether the infection is bacterial or viral, b) the type of bacteria, allowing the 
development and use of narrow spectrum antimicrobials, c) the eventual presence of 
genetic determinant of resistance and d) the actual predicted susceptibility to 
antimicrobials of the isolate.  Efforts are still necessary and ongoing, in particular for 
points c) and d). 
The time to complete the analyses remains an important factor with most sequencing 
technologies.  This is not a concern for infections with slow-growing bacteria, such as 
tuberculosis, for which the advantages of sequencing over culture-based assays makes 
no doubt (see Votintseva et al., 2017; Walker et al., 2015).  For faster-growing 
pathogens, the possibility to fully replace phenotypic testing remains to be evaluated, 
despite high accuracy in reported prediction rates. 
Advances in sequencing technologies also shorten of time between sample acquisition 
and AMR prediction.  For example, studies showed that, in the treatment of patients with 
urinary tract infections, metagenomics analyses on nanopore sequencing data provided 
information to adapt antimicrobial treatment in time for the second dose, within 8 hours 
of the first (Schmidt et al., 2017).   
It provides information (in addition to AMR predictions) that can help in 
understanding outbreaks and guide intervention.  
NGS is, by its technical nature, a technology able to provide a "complete" set of data on 
the genetic material in the analysed sample.  The same data can then be analysed, 
through separate bioinformatics processes, to answer different questions.  
If established around NGS, the same diagnostics/monitoring framework can provide 
information on many crucial aspects in addition to the resistance determinants for AMR, 
such as epidemiological typing for outbreak investigation, organism species and virulence 
factors of clinical relevance (Eyre et al., 2012; Quick et al., 2015).  
By storing WGS sequence data, it is possible to retroactively analyse when new 
information appear. 
7 
 
This "completeness" of information includes the possibility for future analyses which were 
not planned or known to be relevant at the time the samples were sequenced, such as 
the rise and spread of new AMR. This was seen with the recent discovery of the mcr-1 
gene in colistin resistance and its retrospective monitoring in established genome 
sequence databases (Falgenhauer et al., 2016; Hasman et al., 2015) 
It provides mechanistic information about the resistance. 
Unlike phenotypic tests that provide information only regarding resistance/susceptibility 
to antimicrobials, NGS can reveal the molecular basis for this resistance. This information 
can feed in monitoring schemes, helping to understand the events leading to acquisition 
of resistance. In addition, NGS can characterise novel resistance mechanisms when they 
arise, through sequencing of isolates that are phenotypically proven to be resistant.  This 
is a remarkable added value if compared to other nucleic-acid based techniques such as 
the polymerase chain reaction (PCR).  
It is a technology that has potential to link the different fields: clinics, 
environment, food and animals. 
Standardised methods for AMR monitoring that are specifically applicable to the 
environment have never been developed; culture-dependent methods established for 
clinical samples can't readily be applied to environmental samples (Berendonk et al., 
2015) since the numbers of isolates necessary for the tests endpoints are different (set 
of species/prevailing species), most environment bacteria are not recovered in culture 
conditions and established criteria are not applicable (the main objective of these tests 
being to identify likelihood of therapeutic failure). In addition, AMR in non-pathogenic 
environmental bacteria (for which there are no guidelines) is relevant due to the 
possibility of horizontal gene transfer.  
In order to achieve, as described by the Council of the European Union, a coordinated 
surveillance of AMR in humans, food, animals and environment at the EU level, new 
technologies are needed on which to base the framework.  For this, NGS is a strong 
candidate, as extensive work is currently being done with this technology in all the fields. 
Data accumulation allows better understanding and improvement of the system. 
The information available from a set of whole genome sequences grows as the amount of 
available information increases.  Building a monitoring framework on NGS will thus allow 
continuous self-improvement of the whole framework. 
 
2.2 Technical considerations and challenges in the 
implementation of NGS-based methods for AMR determination 
Recently, numerous articles, reports and guidelines, both in the scientific literature and 
regulatory frameworks, have been published assessing and promoting the use of NGS for 
pathogen detection in the clinic, environment and food chain. Although these documents 
often include AMR determination in their discussion, it is becoming clear that the use of 
NGS for AMR has its own - and not always overlapping - set of technical and 
implementation challenges. 
The workshop brought together experts having approached the specific problem of using 
NGS for detecting the genetic determinants of AMR in the different areas.  From these 
discussions, it became apparent that: 
Each field has its own set of technical challenges and realities. 
Despite many studies reporting the use of a common technology, NGS, for AMR 
determination, it is important to note that there exist very specific sets of requirements, 
difficulties and gaps that will need to be addressed on a field-by-field basis.  Outside of a 
simple "monitoring" framework, additional needs can include, for example, proper risk 
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assessment (food, environment) and correct prediction of therapeutic success (human 
and veterinary medicine). 
On a technical basis, considerations of varying relevance include whether the detected 
AMR gene is expressed or not, the presence of the resistance in the chromosome or in a 
plasmid, understanding interaction of bacteria harbouring the resistance with other 
bacteria, the limit of detection of the whole methodology (including the sample 
preparation), etc.   
There are points of contact between the different fields, where the “problems” 
to solve are similar.  
For all these differences, a "core" problem emerged that is common to all fields, which is 
the need to correctly and reliably identify the known genomic determinants of AMR from 
a set of NGS reads produced from the whole genome sequencing of a  sample/isolate. 
Different approaches for this have been and are being developed and used.  There would 
be a lot to gain in involving, in future activities, scientists and experts active in this type 
of work from the different fields in order to share experience and identify best practices. 
Common challenges in this aspect include: 
 Identify a "best practice" bioinformatics strategy and implementation. 
Define what approach to use (shotgun metagenomics, short/long read 
technologies, assembly or single reads analysis, …); minimal metadata 
requirements; how to determine "true" outcome to which the results should be 
compared when evaluating a strategy; minimum recommended sequencing depth; 
etc. 
 What reference database to be used in the analysis. A lot of resources exist, 
such as ResFinder, CARD and SRST2 (see Xavier et al., 2016), which are often 
complemented with in house databases.  The scope and quality of the reference 
database affects the outcome as the AMR screen will only return genetic 
determinants you are looking for. A recent review from a EUCAST subcommittee 
identified the establishment of a sustainable reference database as one of the 
main recommendations towards the use of NGS for bacterial antimicrobial 
susceptibility testing (Ellington et al., 2017). 
 A harmonised way to record and share information. Sharing schemes exist 
and produce benefits, in particular collaborations between national reference 
centres.  However, the situation varies between countries, and the existing 
collaborations rely on ad hoc networks.  In this aspect, the COMPARE project, an 
EU project (funded by Horizon 2020) whose aim is to speed up the detection of 
and response to disease outbreaks among humans and animals through the use 
of NGS, is expected to play an important role.  
 Appropriate quality controls/reference materials/harmonisation. There is 
currently no comprehensive quality management approach in NGS present which 
includes necessary requirements for proper documentation, containing 
standardised information about identified AMR resistance genes, for example.  
Several NGS standardization efforts have been done by American work groups, 
authorities and societies, thus the majority of standardisation efforts has been 
taken place in US. In addition, Illumina Inc., an US-based sequencing company, 
strives towards the establishment of internal developed standards due to the 
current held position as the market leader in NSG. However, due to the strong 
presence and importance of European bodies like CEN (European Committee for 
Standardization), the standardisation of NGS will become inspired and lifted up on 
the EU level in the future. There exists a high demand for NGS standardisation in 
clinical diagnostics, including AMR detection in a clinical setting. However, the 
same standards which will be established there, will not be necessarily applicable 
or reasonable in other application like food chain or environment. Hence, there 
are two options possible. First, the development of one common standard for all 
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possible applications or second, the primary development of NGS standards in a 
clinical setting, which could become translated into other applications like 
environment or food chain later on. The decision for one of these options will rely 
on standardisation bodies and the involved experts.  Efforts in this direction 
should take into account specificities of the field such as fast obsolescence of 
systems and technologies (e.g. 454 and SOLiD), possibly by focusing on setting 
up quality metrics (mainly addressing, in a first instance, NGS performance 
characteristics) and best practices rather than restrictive prescriptions (Endrullat 
et al., 2016; Lambert et al., 2017). 
 
Efforts will also be needed in the optimisation and, possibly, harmonisation of the early 
steps of the workflow - such as a sample preparation, DNA extraction and, if needed, 
target enrichment - as these are expected to have a strong impact on the results.   
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3 Conclusions 
 
Apart from the specific conclusions linked to the different topics, one of the major 
recognised impacts of the workshop was that the experts involved in the different fields 
appreciated the opportunity to meet and interact with experts of other fields of 
applications.  
In the monitoring of AMR in general and in the implementation of NGS technologies in 
particular, each field has its own set of technical challenges, requirements and 
realities.  However, it emerged that there are points of contacts between them, where 
the “problems” to solve are similar.  
In this optic, one of the major requests from the participants was for the JRC to follow up 
this type of discussion in a cross-discipline setup, in order to identify, discuss and 
possibly harmonise the elements which are common to the different fields. 
For some fields, such as human and animal pathogen monitoring (including antibiotics 
resistance), some countries, such as France and the UK, reported ongoing collaborations 
with evident benefits for public health and for the management of outbreaks.  It was 
suggested that understanding (mapping) the situation in the different countries, with a 
possible expanded sharing and coordination effort, would be greatly beneficial. 
It was highlighted that the legislation in the different areas do not always take into 
accounts the importance of AMR monitoring and its translation into intervention, in 
particular in the environment. A need was identified to better understand the abundance 
and processes of AMR spread and evolution in the environment (and its relation to 
environmental and human health). 
For all the effort involved, the experts emphasised the potential benefits of using NGS for 
AMR determination. 
A list of potential follow-up activities has been suggested, as summarised in the Annexes. 
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AMR Antimicrobial Resistance 
ECDC European Centre for Disease Prevention and Control 
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EUCAST European Committee on Antimicrobial Susceptibility Testing 
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Annexes 
 
Annex 1. Proposed follow-up: Mapping the evidence on the risk related to AMR 
between the environment, food producing animals, the food chain and human 
health. 
 
Rationale: An important element in correctly designing and implementing a surveillance 
scheme for AMR spread that would span humans, food, animals and the environment is 
to understand the risk associated with the spread of the genetic determinants of AMR 
between the different frameworks. 
 
Proposal: An expert group should be set up to review the available evidence (see for 
example Ohidul and Tianlin; Williams-Nguyen et al., 2016), assess the demonstrated and 
potential risks and identify existing gaps in the current understanding of the impact of 
antimicrobial resistance spreading between humans, food, animals and the environment.  
A report would be produced and presented to the appropriate policy makers. 
 
Possible impacts: Mapping this evidence and understanding when there is sufficient 
demonstrated risk to justify intervention (and understanding, if not, whether to apply the 
precautionary principle) will help the development of proportional AMR monitoring 
schemes, in particular for the environment which is currently not well developed nor 
encouraged.  It could also lead to the establishment/strengthening of official networks 
between the existing clinic, food and veterinary frameworks in the different Member 
States. It may also affect existing risk assessment regulatory frameworks for 
environmental policies (e.g. the Water Framework Directive 2000/60/EC and the 
Committee for Medicinal Products for Human Use), that currently evaluate safe level of 
antimicrobials in the environment based on their toxicity and do not take into account the 
emergence of AMR, which is expected to occur at lower concentrations (see Bengtsson-
Palme and Larsson, 2016). 
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Annex 2. Proposed follow-up: Harmonisation efforts in the common aspects 
regarding the use of NGS in the detection of AMR common to environment, food 
producing animals, the food chain and human health. 
 
Rationale: In view of the identified points of contacts between the “problems” faced 
when using NGS to identify genetic determinants of AMR whatever the context (clinic, 
food control, environmental monitoring…), there would be added value in continuing 
discussions across the different frameworks. 
 
Proposal: Follow-up discussions should be organised, with the appropriate format to be 
determined (workshops, working groups …) in view of harmonising, as much as possible 
and useful, the common steps and resources.  This could involve: 
 Mapping existing networks in different areas (AMR/metagenomics for human 
health, animal health, food monitoring and environmental monitoring, AMR 
sequence databases, …).  When missing, such a network could be initiated. (E.g. 
application of metagenomics for human health) 
 Invite representatives from these networks (in particular, bioinformaticians) to 
identify and discuss the elements which are truly common between the different 
frameworks (to confirm/complement those identified during the present 
workshop).  
 Identify the best forum to proceed with efforts to identify best practices, quality 
aspects, reference databases, etc. 
Possible impacts: With the current impetus for the eventual establishment of an 
efficient and useful AMR monitoring framework that combines all the different aspects of 
the “One Health” initiative and the environment, it will be invaluable that the elements 
that can be harmonised are harmonised. 
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Annex 3: Workshop agenda 
  
 1st day: 21 March 2017 
 
9:30   - 10:00 Arrival and coffee 
 
10:00 - 10:30 Welcome and opening remarks  
   
  Setting the scene: background, format & aim of the workshop 
  (Guy Van den Eede, JRC) 
 
  Session 1: Added value of NGS technologies in the AMR action plan 
  
10:30 - 12:30 Invited presentations (15 min each), followed by round table  
  discussions  
  Introductory presentations by: 
  Dr Kok Gan Chan, University of Malaya, Malaysia 
  Dr Thierry Naas, Hôpital de Bicêtre- Service de Bactériologie, France 
  Dr Justin O'Grady, University of East Anglia, UK 
  
12:30 - 14:00 LUNCH BREAK  
 
  Session 2: Technical considerations 
  
14:00  - 15:00 Invited presentations (15 min each), followed by round table  
  discussions  
  Introductory presentations by: 
  Dr Thomas Berendonk, Technische Universität Dresden, Germany  
  Dr Derrick Crook, University of Oxford, UK 
  Dr Dirk Höper, Friedrich-Loeffler-Institut- Federal Research Institute 
  for Animal Health, Germany 
  Dr Ole Lund, Technical University of Denmark, Denmark 
   
15:00-15:30 coffee break   
  
15:30  - 17:30 Continuation of discussions 
  
17:30  End of day 1 
  
20:00  WORKSHOP DINNER (Villa Borghi)  
 
 
 
 2nd  day: 22 March 2017 
 
  Session 3: Implementation 
  
9:30  - 10:45 Invited presentations (15 min each), followed by round table  
  discussions. 
  Introductory presentations by: 
  Dr Burton Blais, Canadian Food Inspection Agency, Canada 
  Dr Christoph Endrullat, German Institute for Standardization (DIN),  
  Germany 
  Dr Jessica Vamathevan, European Bioinformatics Institute (EMBL- 
  EBI), UK 
  
10:45-11:15 coffee break   
  
11:15  - 12:30 Continuation of discussions 
  
12:30-13:30 LUNCH BREAK  
 
   Session 4: Conclusions and recommendations 
  
13:30  - 15:00 Summary of the conclusions from the different sessions. Identification 
  of the next steps and follow-up activities  
  
15:00  End of Workshop 
  
 
JRC Ispra, 21-22 March, 2017 JRC WORKSHOP:  THE ROLE AND IMPLEMENTATION OF NEXT-GENERATION SEQUENCING 
TECHNOLOGIES IN THE COORDINATED ACTION PLAN AGAINST ANTIMICROBIAL 
RESISTANCE. 
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